Comparative Pharmacology
Head-to-head clinical analysis: SODIUM PERTECHNETATE TC 99M versus XOFIGO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SODIUM PERTECHNETATE TC 99M versus XOFIGO.
SODIUM PERTECHNETATE TC 99M vs XOFIGO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sodium pertechnetate Tc-99m is a radiopharmaceutical that emits gamma rays (140 keV). The pertechnetate anion (TcO4−) is taken up by the thyroid gland via the sodium-iodide symporter (NIS) and also distributes in salivary glands, gastric mucosa, and choroid plexus. It acts as a diagnostic imaging agent by localizing in tissues via active transport or diffusion, allowing external detection with gamma cameras.
Radium-223 dichloride is a calcium-mimetic alpha particle-emitting radiopharmaceutical that forms complexes with bone mineral hydroxyapatite at areas of increased bone turnover, such as bone metastases. The alpha particles induce double-strand DNA breaks in adjacent cells, resulting in cytotoxic effects.
370-1110 MBq (10-30 mCi) intravenously as a single dose for brain imaging; 370-740 MBq (10-20 mCi) intravenously for thyroid imaging; 185-370 MBq (5-10 mCi) intravenously for salivary gland imaging.
55 kBq (1.49 microcurie) per kg body weight, intravenous injection every 4 weeks.
None Documented
None Documented
Terminal elimination half-life: approximately 6 hours. Clinical context: Allows for imaging up to several hours post-injection; clearance is delayed in renal impairment.
The terminal elimination half-life of radium-223 dichloride is approximately 11 days (range 7–14 days), reflecting the slow turnover of radium in bone.
Renal: approximately 30-50% of the injected dose is excreted in urine within 24 hours. The remainder is eliminated via the hepatobiliary system into feces.
Radium-223 dichloride is primarily excreted via the feces. Approximately 75% of the administered dose is eliminated in feces within 7 days, with a smaller fraction (about 5%) excreted in urine.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical